Improving the Cataract Patient Experience: Minimizing Pain and Inflammation While Reducing the Need for Topical Drops | ASCRS
CME Activity
Improving the Cataract Patient Experience: Minimizing Pain and Inflammation While Reducing the Need for Topical Drops
September 2019

CME Activity Details

Activity Availability

This CME activity is available to all ophthalmologists. Click the button below to access this activity in the CME 24/7 portal. 

Begin Activity Now

Description

Enjoy this 60-minute CME activity in which a panel of experts discuss the improvement of pain and inflammation in the cataract patient. Topics include the impact of pain and inflammation, an overview of current and emerging approaches to minimize topical drops, and a discussion on reimbursement models.

CME Information

This activity is supported by educational grants from EyePoint Pharmaceuticals, Ocular Therapeutix, Omeros, and ImprimisRx.
Credits
: By completing this activity you will earn 1.0 AMA PRA Category 1 Credits™.
Activity Expiration Date: August 31, 2020

Learning Objectives

Upon successful completion of this activity, participants should be able to:

  • Compare and contrast current and emerging regimens and pharmaceutical approaches for the prevention of pain and inflammation in cataract surgery, including alternative therapeutic options designed to overcome patient compliance concerns and reduce ocular toxicity
    • Advanced topical medications
    • Intracameral medications
    • Sustained release technologies
  • Determine adjustments needed to pre-, intra-, and postoperative steroid and NSAID regimens for patients at greater risk for inflammation
  • Discuss cataract patients’ perceptions of intra- and postoperative pain and the impact that it has on surgical outcomes and patient satisfaction
  • Describe evolving reimbursement models to expand access to new approaches to control pain and inflammation after cataract surgery

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.